Dendreon has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Georgia. The company expects to manufacture PROVENGE (sipuleucel-T), for patients with advanced prostate cancer, in the new manufacturing plant. The state of Georgia will inaugurate the plant on September 30, said the company.
If approved by the FDA, Dendreon would launch PROVENGE from its existing facility in Morris Plains, New Jersey, and then ramp up additional manufacturing capacity at its other facilities under development in Union City and Seal Beach, California.
Mitchell Gold, president and chief executive officer of Dendreon, said: We are pleased to announce that we are expanding our manufacturing capacity with the addition of two new facilities in Atlanta and Los Angeles. We have particularly enjoyed partnering with the state of Georgia, Fulton County officials and the local community during this process and are grateful for their partnership and support as we prepare to commercialize PROVENGE to help the many patients with advanced prostate cancer who currently have few appealing treatment options.